Simmiparib

希明哌瑞

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSimmiparib
Drug Alias NameSMOCL-9112SOMCL-9112
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Inactive CompaniesShanghai Acebright Pharmaceuticals Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A